Holen Sie sich die Stockscreener-App
17.18
1.26%
-0.22
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$17.40
Offen:
$17.13
24-Stunden-Volumen:
3.51M
Relative Volume:
2.13
Marktkapitalisierung:
$1.50B
Einnahmen:
$203.45M
Nettoeinkommen (Verlust:
$-351.45M
KGV:
-3.8009
EPS:
-4.52
Netto-Cashflow:
$-369.41M
1W Leistung:
-0.81%
1M Leistung:
-3.81%
6M Leistung:
+147.19%
1J Leistung:
+106.00%
1-Tages-Spanne:
$17.13
$17.88
1-Wochen-Bereich:
$16.66
$18.03
52-Wochen-Spanne:
$5.12
$20.33
Travere Therapeutics Inc Stock (TVTX) Company Profile
Firmenname
Travere Therapeutics Inc
Sektor
Branche
Telefon
888-969-7879
Adresse
3611 VALLEY CENTRE DR, SAN DIEGO
Vergleichen Sie TVTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
17.18 | 1.50B | 203.45M | -351.45M | -369.41M | -4.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-21 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-09 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-12-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-20 | Eingeleitet | Citigroup | Neutral |
| 2023-09-22 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-05-22 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-05 | Hochstufung | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-21 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Hold |
| 2022-12-05 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-21 | Eingeleitet | Bryan Garnier | Sell |
| 2022-07-14 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-26 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
Travere Therapeutics, Inc. (NASDAQ:TVTX) Holdings Decreased by State Street Corp - MarketBeat
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy - The Eastern Progress Online
XTX Topco Ltd Cuts Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Travere Therapeutics: Cautiously Bullish Based On Improving Revenue (NASDAQ:TVTX) - Seeking Alpha
Travere Therapeutics' SWOT analysis: stock poised for growth amid rare disease focus - Investing.com Canada
(TVTX) Investment Analysis - Stock Traders Daily
Y Intercept Hong Kong Ltd Lowers Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Fmr LLC Acquires 31,772 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Travere Therapeutics' SWOT analysis: rare disease stock poised for growth By Investing.com - Investing.com Canada
TVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the Firm - The Eastern Progress Online
Charles Schwab Investment Management Inc. Sells 1,184 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Two Sigma Advisers LP Increases Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock Holdings Lessened by Point72 Asia Singapore Pte. Ltd. - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Jacobs Levy Equity Management Inc. - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Parkman Healthcare Partners LLC Grows Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
HighVista Strategies LLC Decreases Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Bellevue Group AG Takes Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Walleye Capital LLC Has $6.83 Million Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Healthcare of Ontario Pension Plan Trust Fund Purchases 228,300 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Travere Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Travere Therapeutics' SVP Calvin Sandra sells $221,257 in stock By Investing.com - Investing.com Nigeria
Travere Therapeutics' SVP Calvin Sandra sells $221,257 in stock - Investing.com India
Travere Therapeutics to Present at Evercore and Citi Healthcare Conferences in December | TVTX Stock News - StockTitan
Connor Clark & Lunn Investment Management Ltd. Increases Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Oppenheimer & Co. Inc. Buys Shares of 48,139 Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level - Yahoo! Voices
Travere: Q3 Earnings Snapshot - AOL
Los Angeles Capital Management LLC Has $391,000 Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
3 Under-the-Radar Healthcare Companies - MSN
When (TVTX) Moves Investors should Listen - Stock Traders Daily
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
ARMISTICE CAPITAL, LLC Acquires Significant Stake in Travere The - GuruFocus.com
Woodline Partners LP Expands Stake in Travere Therapeutics Inc - GuruFocus.com
Deep Track Capital, LP Reduces Stake in Travere Therapeutics Inc - GuruFocus.com
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $22.00 - MarketBeat
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Travere Therapeutics Awards 24,400 RSUs to New Employees in Talent Acquisition Push | TVTX Stock News - StockTitan
Alport Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Eloxx Pharmac, Biogen, River 3 Renal Corp, Travere Therapeutics, Chinook Therapeutics - The Globe and Mail
Travere Therapeutics Completes $143.8 Million Public Offering - Marketscreener.com
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares - The Manila Times
Finanzdaten der Travere Therapeutics Inc-Aktie (TVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Travere Therapeutics Inc-Aktie (TVTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER |
Nov 25 '24 |
Sale |
18.30 |
12,090 |
221,258 |
54,927 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):